Safety and Efficacy Study of Cefepime/VNRX-5133 in Patients With Complicated Urinary Tract Infections

  • STATUS
    Recruiting
  • participants needed
    582
  • sponsor
    Venatorx Pharmaceuticals, Inc.
Updated on 28 September 2021
Investigator
VenatoRx
Primary Contact
Site 189001 (3.7 mi away) Contact
+102 other location
meropenem
cefepime
pyelonephritis
acute pyelonephritis

Summary

This study will assess the safety and efficacy of cefepime/VNRX-5133 compared with meropenem in both eradication of bacteria and in symptomatic response in patients with cUTIs.

Details
Condition Urinary tract infection, Recurrent Urinary Tract Infection, Recurrent Urinary Tract Infections, Acute Pyelonephritis, Urinary Tract Infections, pyelonephritis, acute, urinary tract infection (uti), urinary infection, recurrent utis
Treatment Meropenem, Cefepime/VNRX-5133, Cefepime/VNRX-5133 (taniborbactam)
Clinical Study IdentifierNCT03840148
SponsorVenatorx Pharmaceuticals, Inc.
Last Modified on28 September 2021

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note